Strikingly, all the GPCR drugs that have been reported to significantly hamper cancer cell line growth in a recent systematic screen29 indeed target receptors of axes that we found significantly correlated with patient survival, with a particular emphasis on receptors for neurotransmitters and adenosine. This evidence concerns the gene LPAR3 and cancer.